Committee expands newborn screening duties

Summary#

A-5705, titled “Expands responsibilities of Newborn Screening Advisory Review Committee,” is an introduced bill that amends and adds to New Jersey’s 2019 newborn-screening law. Its stated goal is to broaden the committee’s work on newborn screening and emerging developments related to genetics and inherited disorders. It is not law, and passage is uncertain.

  • The committee must review and advise the Commissioner of Health on screening, treatment, education, follow-up, and new developments related to newborn screening, genetics, and early identification of inherited disorders.
  • The committee must include consultants with expertise in diagnosing and treating screened disorders and providing genetic counseling. It must meet annually, allow public input, and recommend improvements to the program.
  • Starting in 2027, the committee must review certain disorders on the federal Recommended Uniform Screening Panel within set deadlines, if a screening test is available and the FDA has approved a treatment or therapeutic intervention.
  • The committee must review eight named disorders from October 1, 2027, through October 1, 2028, using those same criteria. A recommendation does not itself add a disorder to New Jersey’s screening program: the Commissioner must approve it.
  • If the Commissioner approves a recommendation for one of those eight disorders, the Department of Health must put screening policies and procedures in place at least 60 days before requiring the screening. If the Commissioner rejects a recommendation, the reasons must be shared with the committee and made public.

What it means for you#

  • Families and newborns: The bill does not itself require screening for the eight named disorders or guarantee that they will be added. Screening would require a committee recommendation and the Commissioner’s approval.
  • Families and the public: The committee must allow public input, but the bill does not set out how people can provide it.
  • The committee and Health Department: They would have new review, recommendation, rule-making, and reporting duties. The bill also requires the Commissioner to adopt regulations to carry it out.
  • Taxpayers: The bill may require staff time and other resources, but it gives no cost estimate.
  • The bill does not directly change a tax, fee, or individual eligibility for a benefit. The supplied material does not include the full 2019 law, so the existing screening rules and how these changes would interact with them could not be independently verified.

Money#

No publicly available information on the bill’s cost.

  • The bill requires committee reviews, a report, and regulations, but provides no estimate of staffing or other costs.
  • It does not specify an appropriation, fee, or source of funding.

What is unclear#

  • The committee must report by January 1, 2028, but its review of the eight named disorders is not due to finish until October 1, 2028. The bill does not explain how the report should cover that unfinished review.
  • The bill does not give a process or deadline for the Commissioner’s decision on recommendations, apart from the requirement to explain and publicize a rejection.
  • It does not explain how public input will work or how the committee will decide whether evidence meets the review criteria.
  • The bill does not specify how many people or how much funding the new duties will require.
  • The supplied material does not include the full parent law, so the precise current screening requirements and any overlap with existing procedures are not confirmed.

Case for#

  • A possible argument for the bill is that regular reviews could help New Jersey consider new screening tests and treatments as they become available.
  • Requiring an available test and an FDA-approved treatment or intervention sets conditions for these reviews rather than requiring automatic adoption of every disorder.
  • Adding diagnostic, treatment, and genetic-counseling expertise could give the committee relevant knowledge when it reviews disorders.
  • Public input and public explanations for rejected recommendations could make the process more open.

Case against#

  • The bill requires reviews and recommendations, not the addition of disorders to the screening program. The Commissioner can reject a recommendation.
  • Requiring an FDA-approved treatment or intervention may leave some disorders outside the review process even when other forms of care or intervention exist.
  • The report deadline comes before the scheduled completion of the named-disorder review, leaving unclear what the report will be able to say about it.
  • The bill adds duties without stating how they will be staffed or funded.